These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 21830207)
1. Elimination of autoreactive B cells in humanized SCID mouse model of SLE. Kerekov NS; Mihaylova NM; Grozdev I; Todorov TA; Nikolova M; Baleva M; Nikolova M; Prechl J; Erdei A; Tchorbanov AI Eur J Immunol; 2011 Nov; 41(11):3301-11. PubMed ID: 21830207 [TBL] [Abstract][Full Text] [Related]
2. An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes. Voynova E; Tchorbanov A; Prechl J; Nikolova M; Baleva M; Erdei A; Vassilev T Immunol Lett; 2008 Mar; 116(2):168-73. PubMed ID: 18262286 [TBL] [Abstract][Full Text] [Related]
3. Re-establishing tolerance to DNA in humanized and murine models of SLE. Nikolova K; Mihaylova N; Voynova E; Kerekov N; Gesheva V; Prechl J; Nikolova M; Tchorbanov A Autoimmun Rev; 2010 May; 9(7):499-502. PubMed ID: 20149897 [TBL] [Abstract][Full Text] [Related]
4. Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity. Dimitrova I; Gesheva V; Nikolova K; Mihaylova N; Todorov T; Nikolova M; Tchorbanov A Lupus; 2010 Oct; 19(11):1261-71. PubMed ID: 20530521 [TBL] [Abstract][Full Text] [Related]
5. Suppression of dsDNA-specific B lymphocytes reduces disease symptoms in SCID model of mouse lupus. Gesheva V; Kerekov N; Nikolova K; Mihaylova N; Todorov T; Nikolova M; Tchorbanov A Autoimmunity; 2014 May; 47(3):162-72. PubMed ID: 24502777 [TBL] [Abstract][Full Text] [Related]
8. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077 [TBL] [Abstract][Full Text] [Related]
9. Blockade of TLR9 signaling in B cells impaired anti-dsDNA antibody production in mice induced by activated syngenic lymphocyte-derived DNA immunization. Chen M; Zhang W; Xu W; Zhang F; Xiong S Mol Immunol; 2011 Jul; 48(12-13):1532-9. PubMed ID: 21592581 [TBL] [Abstract][Full Text] [Related]
10. Suppression of autoreactive T and B lymphocytes by anti-annexin A1 antibody in a humanized NSG murine model of systemic lupus erythematosus. Mihaylova N; Chipinski P; Bradyanova S; Velikova T; Ivanova-Todorova E; Chausheva S; Herbáth M; Kalinova D; Prechl J; Kyurkchiev D; Tchorbanov AI Clin Exp Immunol; 2020 Mar; 199(3):278-293. PubMed ID: 31724735 [TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Yu P; Wellmann U; Kunder S; Quintanilla-Martinez L; Jennen L; Dear N; Amann K; Bauer S; Winkler TH; Wagner H Int Immunol; 2006 Aug; 18(8):1211-9. PubMed ID: 16798839 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. Mihaylova N; Voynova E; Tchorbanov A; Dolashka-Angelova P; Bayry J; Devreese B; Kaveri S; Vassilev T Mol Immunol; 2009 Nov; 47(1):123-30. PubMed ID: 19243823 [TBL] [Abstract][Full Text] [Related]
14. [B-cell anomalies in systemic lupus erythematosus]. Tron F; Jacquot S; Gilbert D Ann Med Interne (Paris); 2002 Dec; 153(8):503-12. PubMed ID: 12610424 [TBL] [Abstract][Full Text] [Related]
15. Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development. Enghard P; Humrich JY; Chu VT; Grussie E; Hiepe F; Burmester GR; Radbruch A; Berek C; Riemekasten G Eur J Immunol; 2010 Jun; 40(6):1809-18. PubMed ID: 20333624 [TBL] [Abstract][Full Text] [Related]
16. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Zhao Z; Weinstein E; Tuzova M; Davidson A; Mundel P; Marambio P; Putterman C Arthritis Rheum; 2005 Feb; 52(2):522-30. PubMed ID: 15693007 [TBL] [Abstract][Full Text] [Related]
17. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. Takahashi K; Kozono Y; Waldschmidt TJ; Berthiaume D; Quigg RJ; Baron A; Holers VM J Immunol; 1997 Aug; 159(3):1557-69. PubMed ID: 9233655 [TBL] [Abstract][Full Text] [Related]
19. Self-peptides in the initiation of lupus autoimmunity. Bockenstedt LK; Gee RJ; Mamula MJ J Immunol; 1995 Apr; 154(7):3516-24. PubMed ID: 7534800 [TBL] [Abstract][Full Text] [Related]
20. A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. James JA; Harley JB J Immunol; 1998 Jan; 160(1):502-8. PubMed ID: 9552009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]